CT lung cancer screening no cure-all for smokersJune 10, 2008Screening for lung cancer with computed tomography (CT) may help reduce lung cancer deaths in current and former smokers, but it won't protect them from other causes of death associated with smoking, according to a new study published in the July issue of the journal Radiology. "Our study suggests that screening may be one way to reduce risk of death from lung cancer," said the study's lead author, Pamela McMahon, Ph.D., senior scientist at Massachusetts General Hospital and instructor in radiology at Harvard Medical School in Boston. "However, the number-one goal should still be to quit smoking, because it will reduce risk of death from many causes, including lung cancer." According to the Centers for Disease Control and Prevention, lung cancer is the leading cause of cancer death in the U.S. and is responsible for more deaths annually than breast, prostate and colon cancers combined. The American Cancer Society estimates 168,840 U.S. deaths will be attributable to lung cancer in 2008. Approximately 87 percent of lung cancers are caused by smoking. Smoking is also related to deaths from several other types of cancer, as well as heart and respiratory diseases. For the study, researchers at Harvard and the Mayo Clinic in Rochester, Minn., set out to determine the long-term effectiveness of CT screening for lung cancer by entering data from Mayo's helical CT screening study of 1,520 current and former smokers into the Lung Cancer Policy Model (LCPM), a comprehensive simulation model of lung cancer development, screening findings, treatment results and long-term outcomes. Using the model allowed researchers to interpret available data while waiting for long-term, randomized clinical trials to be completed. "We used a carefully developed computer model of lung cancer to simulate individuals who smoke and/or develop lung cancers and go on to get screened or treated," Dr. McMahon said. "It's sort of like the computer game 'The Sims,' except there are no graphics, and smoking and lung cancer are the main events." The LCPM projections showed that, at six-year follow-up, the patients who had undergone five annual screenings had an estimated 37 percent relative increase in lung cancer detection, compared with those who had not been screened. The relative reduction in lung cancer-specific mortality was 28 percent. However, reduction in all-cause mortality was only 4 percent. Fifteen-year follow-up showed relative reductions in lung cancer-specific mortality of 15 percent and all-cause mortality of 2 percent. "Our study fills in a piece of the puzzle but does not solve it," Dr. McMahon said. "We are hopeful that randomized trials conducted by the National Cancer Institute will show a benefit from screening. Until then, patients should think carefully about undergoing a test that has no direct evidence of benefit." Radiological Society of North America |
|||||||||||||||||||||
| Related Lung Cancer Current Events and Lung Cancer News Articles Study of concurrent radiotherapy, chemotherapy shows promise in small cell lung cancer Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results. Stereotactic radiotherapy offers noninvasive, effective treatment for frail patients with early-stage lung cancer Stereotactic body radiation therapy (SBRT) should be considered a new standard of care for early-stage lung cancer treatment in patients with co-existing medical problems, according to results from a national clinical trial led by UT Southwestern Medical Center physicians. Preventative brain radiation for lung cancer patients: Benefits and risks A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain. Study spotlights efficacy of questionnaire to identify patients at high risk for lung cancer A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Intervals between lung cancer diagnosis and treatment displays a health care disparity Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies. Researchers use drug-radiation combo to eradicate lung cancer Researchers at UT Southwestern Medical Center have eliminated non-small cell lung (NSCL) cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation. Experts issue call to reconsider screening for breast cancer and prostate cancer Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece published in the "Journal of the American Medical Association." Detecting the undetectable in prostate cancer screening A team of Northwestern University researchers, using an extremely sensitive tool based on nanotechnology, has detected previously undetectable levels of prostate-specific antigen (PSA) in patients who have undergone radical prostatectomy. New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation. African American lung cancer patients may have different response to new cancer-fighting drugs Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs. More Lung Cancer Current Events and Lung Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||